MorphoSys increases financial guidance

MorphoSys AG has increased its financial guidance for 2017 in the wake of a licensing deal with I-Mab Biopharma, a biologics company based in Shanghai, China. The agreement gives I-Mab the right to develop the German company’s antibody for multiple myeloma for the Chinese market.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany